608 related articles for article (PubMed ID: 25345753)
1. Anti-inflammatory agents to treat or prevent type 2 diabetes, metabolic syndrome and cardiovascular disease.
Esser N; Paquot N; Scheen AJ
Expert Opin Investig Drugs; 2015 Mar; 24(3):283-307. PubMed ID: 25345753
[TBL] [Abstract][Full Text] [Related]
2. Antidiabetic agents: Potential anti-inflammatory activity beyond glucose control.
Scheen AJ; Esser N; Paquot N
Diabetes Metab; 2015 Jun; 41(3):183-94. PubMed ID: 25794703
[TBL] [Abstract][Full Text] [Related]
3. Cooling down inflammation in type 2 diabetes: how strong is the evidence for cardiometabolic benefit?
Maiorino MI; Bellastella G; Giugliano D; Esposito K
Endocrine; 2017 Feb; 55(2):360-365. PubMed ID: 27230767
[TBL] [Abstract][Full Text] [Related]
4. Salsalate: a pleotropic anti-inflammatory drug in the treatment of diabetes, obesity, and metabolic diseases.
Hasan I; Rainsford KD; Ross JS
Inflammopharmacology; 2023 Dec; 31(6):2781-2797. PubMed ID: 37758933
[TBL] [Abstract][Full Text] [Related]
5. Insulin resistance and chronic cardiovascular inflammatory syndrome.
Fernández-Real JM; Ricart W
Endocr Rev; 2003 Jun; 24(3):278-301. PubMed ID: 12788800
[TBL] [Abstract][Full Text] [Related]
6. The role of inflammation and macrophage accumulation in the development of obesity-induced type 2 diabetes mellitus and the possible therapeutic effects of long-chain n-3 PUFA.
Oliver E; McGillicuddy F; Phillips C; Toomey S; Roche HM
Proc Nutr Soc; 2010 May; 69(2):232-43. PubMed ID: 20158940
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the relationship between obesity, inflammation, and insulin resistance.
Bastard JP; Maachi M; Lagathu C; Kim MJ; Caron M; Vidal H; Capeau J; Feve B
Eur Cytokine Netw; 2006 Mar; 17(1):4-12. PubMed ID: 16613757
[TBL] [Abstract][Full Text] [Related]
8. Expert Group Consensus Opinion: Role of Anti-inflammatory Agents in the Management of Type-2 Diabetes (T2D).
Das AK; Kalra S; Tiwaskar M; Bajaj S; Seshadri K; Chowdhury S; Sahay R; Indurkar S; Unnikrishnan AG; Phadke U; Pareek A; Purkait I
J Assoc Physicians India; 2019 Dec; 67(12):65-74. PubMed ID: 31801334
[TBL] [Abstract][Full Text] [Related]
9. Inflammatory markers and cardiometabolic diseases.
Esser N; Paquot N; Scheen AJ
Acta Clin Belg; 2015 Jun; 70(3):193-9. PubMed ID: 26103538
[TBL] [Abstract][Full Text] [Related]
10. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
Yamagishi S; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
[TBL] [Abstract][Full Text] [Related]
11. Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.
Leiter LA; Lewanczuk RZ
Am J Hypertens; 2005 Jan; 18(1):121-8. PubMed ID: 15691626
[TBL] [Abstract][Full Text] [Related]
12. Visceral fat resection in humans: effect on insulin sensitivity, beta-cell function, adipokines, and inflammatory markers.
Lima MM; Pareja JC; Alegre SM; Geloneze SR; Kahn SE; Astiarraga BD; Chaim ÉA; Baracat J; Geloneze B
Obesity (Silver Spring); 2013 Mar; 21(3):E182-9. PubMed ID: 23404948
[TBL] [Abstract][Full Text] [Related]
13. Impact of anti-inflammatory nutrients on obesity-associated metabolic-inflammation from childhood through to adulthood.
Connaughton RM; McMorrow AM; McGillicuddy FC; Lithander FE; Roche HM
Proc Nutr Soc; 2016 May; 75(2):115-24. PubMed ID: 26934951
[TBL] [Abstract][Full Text] [Related]
14. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
15. The role of multicomponent therapy in the metabolic syndrome, inflammation and cardiovascular risk in obese adolescents.
Masquio DC; de Piano A; Campos RM; Sanches PL; Carnier J; Corgosinho FC; Netto BD; Carvalho-Ferreira JP; Oyama LM; Nascimento CM; de Mello MT; Tufik S; Dâmaso AR
Br J Nutr; 2015 Jun; 113(12):1920-30. PubMed ID: 25907896
[TBL] [Abstract][Full Text] [Related]
16. Modified Si-Miao-San extract inhibits inflammatory response and modulates insulin sensitivity in hepatocytes through an IKKβ/IRS-1/Akt-dependent pathway.
Liu K; Luo T; Zhang Z; Wang T; Kou J; Liu B; Huang F
J Ethnopharmacol; 2011 Jul; 136(3):473-9. PubMed ID: 21296137
[TBL] [Abstract][Full Text] [Related]
17. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
Tjokroprawiro A
Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
[TBL] [Abstract][Full Text] [Related]
18. Insulin resistance and inflammation in the early phase of type 2 diabetes: potential for therapeutic intervention.
Schernthaner GH; Schernthaner G
Scand J Clin Lab Invest Suppl; 2005; 240():30-40. PubMed ID: 16112958
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-targeted therapy for metabolic syndrome and type 2 diabetes.
Maedler K; Dharmadhikari G; Schumann DM; Størling J
Handb Exp Pharmacol; 2011; (203):257-78. PubMed ID: 21484575
[TBL] [Abstract][Full Text] [Related]
20. 11β-Hydroxysteroid dehydrogenase type 1: relevance of its modulation in the pathophysiology of obesity, the metabolic syndrome and type 2 diabetes mellitus.
Pereira CD; Azevedo I; Monteiro R; Martins MJ
Diabetes Obes Metab; 2012 Oct; 14(10):869-81. PubMed ID: 22321826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
